What about the recent large, randomized controlled trials that seem to show ivermectin is not effective for COVID-19?

Many of the trials have extreme conflicts of interest and appear to have been designed to fail and predetermined to show ivermectin as ineffective.

Many use a monotherapy (e.g., treatment with only one therapeutic) when our frontline physicians have found ivermectin is most effective as part of a treatment protocol that includes other FDA-approved medications and supplements backed by clinical and observational evidence.

The trials often under-dosed and started treatment far too late, even though in the medical community it is common knowledge that COVID-19 becomes far more difficult to treat the longer a patient has had symptoms. Treating early is imperative.

The TOGETHER trial, for example, studied patients who started treatment up to eight days after the onset of symptoms. ACTIV-6 severely limited the use of ivermectin, administering a dose below what is known to be effective on the variants at the time and received too late (6 days on average) after the onset of symptoms. Despite these obvious shortfalls, in ACTIV-6 there was a statistically significant, albeit modest, impact on time to clinical recovery for patients using ivermectin to treat COVID-19. This effect was prominently seen in the more severe patients in the trial, whose symptoms were reduced by an average of three days with ivermectin. FLCCC physicians have understood for nearly 18 months that ivermectin works best against COVID-19 when administered early, in combination with other therapies and given with a fatty meal for at least 5 days or until symptoms resolve.

Trials of generic medicines that are funded and influenced by profit-driven pharmaceutical companies will always fail. We need an independent system dedicated to conducting well-designed trials and transparent research studies of repurposed generic treatments – not just for COVID-19, but for all diseases that may have safe and affordable remedies. The use of independent research is our only hope of understanding how these medicines can best be used to help patients.